BTG plc (LON:BTG) has received a consensus recommendation of “Hold” from the twelve ratings firms that are currently covering the stock, ARN reports. Four investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is GBX 562.56 ($9.46).
A number of analysts have recently weighed in on BTG shares. Analysts at Deutsche Bank reiterated a “buy” rating on shares of BTG plc in a research note on Friday. They now have a GBX 655 ($11.02) price target on the stock. Separately, analysts at N 1 Singer cut their price target on shares of BTG plc from GBX 488 ($8.21) to GBX 486 ($8.17) in a research note on Thursday. They now have a “sell” rating on the stock. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of BTG plc in a research note on Tuesday. They now have a GBX 525 ($8.83) price target on the stock.
BTG plc (LON:BTG) traded up 6.86% during mid-day trading on Friday, hitting GBX 584.50. The stock had a trading volume of 790,490 shares. BTG plc has a 52 week low of GBX 323.10 and a 52 week high of GBX 624.00. The stock has a 50-day moving average of GBX 536. and a 200-day moving average of GBX 553.5.
BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.